Introduction
Acute myeloid leukemia (AML) accounts for approximately 70-80% of acute leukemia in adults. Treatment and outcome of the disease depend on several factors, including leukemia karyotype, molecular alteration and patient age. The 5-year survival rate ranges from 65 to 15%, drastically decreasing with the age at diagnosis. Chromosomal translocations frequently result in dysfunction of transcription factors needed for normal hematopoietic development. Additional mutations have been described in the receptor tyrosine kinases FLT3, c-Kit and c-Fms, as well as in N-and K-Ras. 1, 2 The manifestation of AML is a combination of mutations conferring proliferative advantage, impaired differentiation and apoptosis.
Polypeptide growth factors have been shown to play a key role in AML proliferation and survival. [3] [4] [5] Human AML cells express a variety of growth factor and cytokine receptors that can be activated by mutation, overexpression and/or establishment of autocrine loops. Among these receptors are the polypeptide growth factor receptors FLT3, c-Kit, c-Fms, vascular endothelial growth factor receptor and fibroblast growth factor receptor. [3] [4] [5] [6] [7] [8] Several potential anti-AML therapeutic approaches involving the FLT3 system have been reported. [9] [10] [11] Insulin-like growth factor (IGF) signaling plays a major role in various human malignancies, including breast, colon and prostate cancer. 12 In leukemia, IGF signaling has not yet been extensively studied, although expression of the IGF-I receptor (IGF-IR) was reported in human AML cells. 13, 14 Autocrine IGF-I production has been suggested to play a role in drug resistance in an AML cell line. 15 In addition, IGF-I signaling has a crucial function in other hematological malignancies such as multiple myeloma, 16 and several anti-IGF-IR experimental therapies were shown to inhibit multiple myeloma proliferation in vitro and in vivo. 17 A critical intracellular signaling mediator of the IGF-IR is the phosphoinositide 3-kinase (PI3K)/Akt pathway. 18, 19 Indeed, PI3K signaling is implicated in the control of cell proliferation, survival and motility/metastasis downstream of many different growth factor receptors. 20 The importance of PI3K signaling in human cancer is highlighted by the fact that mutations in the tumor suppressor gene PTEN occur frequently in human tumors. 20, 21 PTEN is a phosphatase that antagonizes the action of PI3K by dephosphorylating the D-3 position of polyphosphoinositides. 22 Moreover, recent reports have described activating mutations in the PIK3CA gene encoding the catalytic p110a isoform of class I A PI3K in a variety of human cancers, including, breast, colon and ovarian cancer. 23, 24 Mutations in the PTEN gene have not been found in a high percentage of AML cases, although they were documented in AML cell lines. 21, 25 Moreover, a recent screen comprising AML cases did not reveal any mutations in the gene encoding p110a, 26 suggesting a possible deregulation of other class I A PI3Ks, namely p110b and p110d in hematological malignancies. In support of this notion, constitutive activation of Akt/PKB has been reported by several studies in human AML blasts. 27, 28 In the context of leukemia, altered PI3K signaling was also shown to play a role in the development of adult T-cell lymphoma. 29 In the present report, we have investigated the expression pattern and biological functions of components of the IGF-IR signaling system in human AML blasts and cell lines. Moreover, we have evaluated the potential of the novel IGF-IR kinase inhibitor NVP-AEW541 30 as an antitumor agent in AML. Finally, we have investigated whether targeting downstream signaling mediators of the IGF-IR could suppress growth and induce apoptosis in AML cell lines. Our findings describe for the first time a role for autocrine signaling by IGF-I and the IGF-IR in growth, survival and chemoresistance of AML cells, which involves the PI3K/Akt pathway.
Materials and methods

Reagents and antibodies
Antibodies and reagents were purchased from the following companies: IGF-IRb, IRb, p85a, p110b, p110d, PTEN, Akt/PKB, Erk1/2, PARP, IGF-I and p-Tyr (Santa Cruz Biotechnology, Santa Cruz, CA, USA); p110a (clone U3A) (generous gift from Dr A Klippel); 16F-11 (Novus Biologicals, Littleton, CO, USA); actin, insulin (Sigma-Aldrich, St Louis, MO, USA); activated Akt/PKB (Ser473, Thr308), activated Erk1/2 (Thr202/Tyr204) (Cell Signalling Technology, Danvers, MA, USA); LY294002, IGF-I, IGF-IR neutralizing antibody (Calbiochem, La Jolla, CA, USA); IR neutralizing antibody (Biosource, Camarillo, CA, USA); siGENOME siRNA (Dharmacon, Lafayette, CO, USA); NVP-AEW541 (Novartis Pharma AG, Basel, Switzerland); TGX-221 (Prof. SP Jackson, Camarillo, CA, USA); IC87114 (ICOS Corporation, Indianapolis, IN, USA).
Cell culture
Human AML cell lines were grown in RPMI (Life Technologies Invitrogen, Carlsbad, CA, USA) with 10% (v/v) fetal calf serum (FCS) and penicillin/streptomycin/L-glutamine and passaged every 3-5 days by dilution. For growth factor stimulations, cells were incubated overnight in Optimem medium (Life Technologies/Invitrogen) and washed with serum-free medium before incubation with growth factors. Immortalized B cells 31 were cultured in RPMI with 20% (v/v) FCS and penicillin/streptomycin/ L-glutamine. Heparinized peripheral blood or bone marrow samples were obtained from adult patients with AML. Each sample contained more than 90% blast cells. AML diagnosis was based on the criteria of the French-American-British Cooperative Group and immunophenotypic studies. Blast cells, isolated by centrifugation on Ficoll-Hypaque, were used immediately or kept frozen until use. Cell viability, as assessed by Trypan blue exclusion, was greater than 80% after 4-12 h of blast cell culture in RPMI medium/10% FCS. Immunophenotypic analysis was performed using a large panel of directly fluorescein isothiocyanate (FITC)-or phycoerythrin-conjugated mAbs reacting with leukocyte differentiation antigens CD-2, -3, -4, -7, -10, -13, -14, -15, -19, -20, -22, -33, -34, -41, -61, glycophorin A, HLA-DR, TdT or myeloperoxidase (antibodies were from Becton Dickinson, Franklin Lake, NJ, USA; Immunotech-Coulter, Miami, FL, USA; DAKO, Troy, MI, USA). Unconjugated mAbs were detected by indirect immunofluorescence using an FITC-conjugated goat anti-mouse antibody (Fab92 fragment; Tago). Double-immunofluorescence analysis was performed with an Epics flow cytometer (Coulter Electronics, Fullerton, CA, USA). 
RT-PCR analysis
ELISA assays
Apoptosis
For detection of apoptosis, AML cells were incubated for 16-24 h in the presence or absence of inhibitors and analyzed for caspase-3 and -7 activity using the Caspase-Glo 3/7 Assay (Promega) according to the manufacturer's instructions. Alternatively, the cells were lysed and caspase-3 activity was measured using the CaspACE Assay System (Promega). Additionally, samples were analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and western blot with anti-poly(ADP-ribose) polymerase (PARP) antibodies.
Transient and stable expression in AML cells
U937 cells were transfected with small interfering RNA (siRNA) targeting the IGF-IR or IR and small hairpin RNA (shRNA) constructs 32 targeting or the parental pRetroSuper vector p110b (PIK3CB) or p110d (PIK3CD) using the Amaxa Nucleofector system (Amaxa biosystems, Gaithersburg, MD, USA) according to the manufacturer's protocol. Cell Line Nucleofector Kit V was used and program V-001 applied. Constructs were from the library described previously. 32 After 48 and 72 h of transfection, cells were analyzed for cell proliferation by an MTS assay and lysed in cell lysis buffer in order to visualize protein expression by SDS-PAGE and western blotting. Alternatively, transfected cells were resuspended in fresh medium containing puromycin at 2 mg/ml and selected for 3-4 weeks. Puromycin-resistant U937 cells were maintained in media containing 2 mg/ml puromycin as stable transfectants.
SDS-PAGE and western blot analysis
Cellular lysates were prepared as described previously, 33 separated by SDS-PAGE, transferred to a hydrophobic polyvinylidene difluoride membrane (Hybond-P; Amersham Biosciences), and immunoblotted with various antibodies according to the manufacturer's protocol. Chemiluminescence was used for visualization using the enhanced chemiluminescence western blotting detection reagents (Amersham Biosciences) according to the manufacturer's protocol.
Immunoprecipitation
Cells were kept in medium without serum and stimulated with IGF-I or insulin for 10 min at 371C. The cells were then lysed in lysis buffer (1% Triton X-100) and incubated with Protein G-Sepharose beads (GE Healthcare, Piscataway, NJ, USA) and a-p-Tyr antibody for 3 h at 41C with mixing. After washing with cold lysis buffer, samples were denatured in SDS-PAGE loading buffer and analyzed by western blot.
Colony-forming assay
Bone marrow CD34 þ cells (Lonza, Basel, Switzerland) were cultured at different densities (200, 500, 1000 per ml) in 1 ml human methylcellulose complete media (HSC004; R&D Systems, Minneapolis, MN, USA) with increasing concentrations of NVP-AEW541. Each condition was evaluated twice in duplicates. Colonies, defined as aggregates 450 cells, were scored after 14 days incubation at 371C in a fully humidified atmosphere with 5% CO 2 . Figures 1a and b) . Consistently, RT-PCR analysis revealed only low mRNA levels of this isoform in AML cell lines (data not shown). In contrast, the class I A PI3K catalytic isoforms p110b and p110d displayed a broader expression pattern in AML blasts and cell lines, and overexpression was found in more than 50% of the blasts. The western blot analysis revealed no significant differences in expression of the downstream signaling intermediate extracellular signal-regulated kinase (Erk) (Supplementary Figure 1c) , while Akt/PKB levels were elevated in the AML blasts, when compared to nonleukemic bone marrow cells. Constitutive activation of Akt/PKB was detected in all AML blasts and cell lines, while some of the blasts and cell lines also displayed detectable activation of Erk1/2.
Results
Characterization of the expression of the IGF-IR, IGFs and signaling intermediates in a panel of human AML blasts and cell lines
The expression of the ligands of the IGF-IR was then investigated in the AML blasts and cell lines by RT-PCR and ELISA. AML cell lines grown under serum-free conditions secreted detectable levels of IGF-I into the culture medium, as assessed by ELISA (Figure 1c ), which correlated with RT-PCR analysis revealing broad expression of the IGF-I mRNA in most of the AML cell lines (Figure 1d ). In contrast, IGF-II expression was restricted to the K562 cell line. The levels of IGF-I and IGF-II secreted in the supernatant of AML cell lines were in the range of 6-12 and 10 ng/ml, respectively. At these concentrations, IGF-I was able to activate downstream signaling events (Figure 2c) , implying that the amounts of IGF-I secreted by AML cells are biologically relevant. IGF-I secretion was also detected in primary AML blasts, confirming the results obtained in cell lines (Figure 1c) . Thus, primary AML blasts and cell lines express the IGF-IR, IR, the ligand IGF-I and downstream signaling mediators such as class I A PI3K isoforms.
IGF-I and insulin promote growth of AML blasts through the PI3K pathway
The ability of IGF-I and insulin to promote growth of human AML blasts in vitro was then investigated. Treatment of isolated blasts with IGF-I or insulin resulted in a two-to fourfold increase in AML blast growth after 48 h in serum-containing medium (Figure 2a) . The optimal concentrations of IGF-I and insulin for promotion of blast growth were 25 and 50 ng/ml, respectively. These results were observed in a panel of human AML blasts including AML M0, M1 and M5. To investigate whether the PI3K pathway was involved in the growthpromoting effects of IGF-I and insulin, AML blasts were treated with the pharmacological inhibitor LY294002 in combination with growth factors. The pharmacological inhibitor impaired IGF-I-and insulin-stimulated growth of primary AML blasts in vitro (Figure 2b) .
The activation of the PI3K and Erk pathways by IGF-I and insulin was then investigated in AML cells by monitoring the phosphorylation status of the downstream targets Akt and Erk1/2. Optimal concentrations of IGF-I (100 ng/ml) and insulin (10-50 nM) resulted in the rapid induction of Akt phosphorylation on Thr308 and Ser473, as well as in phosphorylation of Erk1/2 in U937 cells (Figure 2c) . Comparable results were also obtained in the NB4 cell line and in AML blasts. Thus, IGF-I and insulin promote AML cell growth by activating the PI3K/Akt signaling pathway. Stimulation of U937 and NB4 cells with IGF-I or insulin induced the recruitment of the receptors to phosphotyrosine-containing signaling complexes also containing the insulin receptor substrate-1 and the PI3K regulatory subunit p85a (Figure 2d) .
Downregulation of the PI3K isoforms p110b and p110d impairs AML cell growth, induces apoptosis and impairs Akt activation by IGF-I
The results from the expression analysis of PI3K isoforms in AML blasts and cell lines had revealed consistent expression of the PI3K isoforms p110b and p110d (Supplementary Figure 1b) , indicating a possible role for these enzymes in AML cell responses. Moreover, inhibition of PI3K activity with LY294002 impaired growth of AML blasts induced by IGF-I and insulin (Figure 2b ). An RNA interference (RNAi) approach was used to specifically downregulate the expression of p110b and p110d in U937 cells. Western blot analysis confirmed the specific downregulation of the PI3K isoforms upon transfection with the corresponding (short hairpin) shRNA construct (Figure 3a) . U937 cells stably transfected with either p110b and p110d shRNA displayed reduced growth in serum-containing medium (Figure 3b) . Moreover, the p110b and p110d shRNA-transfected cells were more sensitive to apoptosis induced by serum withdrawal, as assessed by the induction of caspase-3 activation (Figure 3b) .
Resistance of human AML cells to chemotherapy is a frequent cause of treatment failure. Therefore, we next investigated whether downregulation of p110b or p110d could sensitize human AML cells to the action of chemotherapeutic agents. Treatment with cytarabine (Ara-C) or etoposide significantly enhanced the suppression of cell growth in p110d shRNA- (Figure 3d ). To confirm these findings, a pharmacological approach using isoform-specific p110b or p110d inhibitors was also used in U937 cells. The p110b-specific inhibitor TGX-221 34 and the p110d-specific inhibitor IC87114 35 effectively impaired activation of Akt by IGF-I or insulin (Figure 3d ). IC87114 did not affect IGF-I-stimulated Akt phosphorylation in KG-1 cells expressing very low levels of p110d (Figure 3e) , confirming the selectivity of the inhibitor. Together these data show that the class I A PI3K isoforms p110b and p110d play a major role in AML cell growth and survival. In addition, p110d appears to play a selective role in chemoresistance in AML cells. Moreover, p110b and p110d transduce signals from the activated IGF-IR leading to Akt activation in AML cells.
Pharmacological inhibitors of the IGF-IR or neutralizing antibodies impair AML cell growth and induce apoptosis
The ability of the specific IGF-IR kinase inhibitor NVP-AEW541 30 to block AML cell growth in serum-containing medium was then investigated. NVP-AEW541 potently suppressed growth of NB4 and Kasumi cells (IC 50 ¼ 0.7 and 0.4 mM) after 72 h, but was less efficient at inhibiting growth of HL-60 (IC 50 ¼ 6.3 mM), U937 (IC 50 ¼ 7.6 mM) and THP1 (IC 50 ¼ 9.7 mM) (Figures 4a and b) . The inhibitor was also able to suppress growth of AML blasts isolated from patients ( Figure 4a ) with IC 50 values in the range of 2.2-13 mM. Nonleukemic bone marrow cells or immortalized B cells were comparatively resistant to NVP-AEW541. The expression levels of the IGF-IRb, which is the target of NVP-AEW541, did not correlate with the sensitivities of the AML cell lines to the inhibitor (Figures 1a  and 4a) . The highest levels of IR expression were found in some of the cell lines with reduced sensitivity to the inhibitor such as U937 and THP1. In order to rule out potential cytotoxic effects of NVP-AEW541 on normal hematopoiesis, the inhibitor was tested at different concentrations on CD34 þ hematopoietic progenitors from a healthy donor. Whereas high concentrations (10 mM) significantly decreased the colony-forming ability (20% reduction), low concentrations (1-5 mM) of the inhibitor did not significantly affect the response (Figure 4c) .
To confirm the data obtained with the IGF-IR kinase inhibitor, a neutralizing antibody directed against the receptor was tested for its ability to inhibit AML cell proliferation. Three AML cell lines (U937, HL-60 and NB4) were analyzed. A significant inhibition of cell proliferation was observed when all three AML cell lines were treated with the IGF-IR neutralizing antibody, as compared to a control (OKT3) antibody or immortalized B cells (Figure 4d) . Similar results were obtained with a neutralizing antibody against the IR in U937 and HL-60 cells, but not in NB4, which express low levels of the receptor (Figure 1a) .
The ability of the IGF-IR kinase inhibitor to induce apoptosis was then investigated in AML blasts and cell lines. Treatment of purified AML blasts with increasing concentrations of NVP-AEW541 resulted in increased activation of caspase-3 and enhanced cleavage of PARP (Figure 4e ), demonstrating the induction of apoptosis in these cells. Consistently, NVP-AEW541-induced cell death was observed in NB4 and U937 cells, as assessed by propidium iodide (PI) staining and fluorescence-activated cell sorting analysis (Figure 4f ). Reduced cell proliferation was also observed when U937 cells were transfected with siRNA specifically targeting the IGF-IR or IR (Figures 5a and b) , further confirming the results obtained with NVP-AEW541 or neutralizing antibodies.
Inhibition of the IGF-IR kinase activity enhances the effects of apoptosis in AML blasts and cell lines induced by etoposide or Ara-C AML treatment is frequently complicated by resistance to chemotherapy. On that account, we investigated whether inhibition of IGF-IR signaling by NVP-AEW541 could sensitize human AML cells to the action of chemotherapeutic agents. Increasing concentrations of etoposide or Ara-C resulted in effective suppression of cell growth in U937, THP1, HL-60 and NB4 AML cell lines with IC 50 values in the range of 1.0-5.0 mM and 0.1-2.0 mM, respectively (data not shown). AML cells were then exposed to etoposide or Ara-C (1.0 mM each) in the presence of increasing concentrations of NVP-AEW541. Combination treatment enhanced the effect of IGF-IR inhibition in NVP-AEW541-sensitive cells (Figure 6a ), whereas the effect was negligible in cells with lower responsiveness to the inhibitor (Figure 6b ). Already at a low concentration of etoposide (1.0 mM), nontoxic concentrations of NVP-AEW541 increased the effect of the chemotherapeutic drug on NB4 cells (Figure 6a) . Furthermore, combination treatment of etoposide and NVP-AEW541 elevated caspase-3 activity in primary AML blasts and induced PARP cleavage (Figure 6c) , demonstrating enhanced apoptosis. Thus, pharmacological IGF-IR kinase inhibitors sensitize human AML cells to etoposide.
Discussion
Pharmacological inhibitors targeting the tyrosine kinase activity of receptor tyrosine kinase (RTKs) have been extensively studied as antitumor agents, such as in the case of the epidermal growth factor receptor in solid tumors and FLT3 inhibitors in leukemia. 9, 36 Differences in the sensitivities of human tumor cells to such agents can be caused by mutations in the receptor. 37 Thus, in leukemia, FLT3 mutations were reported to correlate with sensitivity of tumor cells to RTK inhibitors. 38 Moreover, FLT3 mutations were recently shown to correlate with decreased patient survival in AML patients. 39 Although activating mutations have not been described in the IGF-IR in most human cancers, the receptor is frequently activated by overexpression and/or establishment of autocrine loops involving the ligands IGF-I and IGF-II. 12, 40 Previous reports have investigated the expression of the IGF-IR in human AML cells and described a role for IGF-I as a growth factor for these cells in combination with other cytokines. 13, 41 Increased serum levels of the IGFBP-2 have also been observed in patients with AML. 42 In the present study, we have further investigated the biological role of IGF-IR signaling in human AML blasts and cell lines. For the first time, we show that IGF-I promotes growth of AML blasts and activates intracellular signaling mediators including the PI3K/Akt and Erk pathways. Expression of the IGF-IR was found in a panel of primary AML blasts and cell lines, and IGF-I was consistently secreted by blasts and cell lines, implying that an autocrine signaling loop involving IGF-I and the IGF-IR is present in AML. Indeed, the levels of IGF-I detected in the supernatant of AML cells were shown to activate intracellular signaling events in the cells, implying that they are biologically relevant. The autocrine signaling loop involving IGF-I may contribute to the constitutive activation of Akt observed in AML blasts and cell lines. Moreover, the related IR was also found overexpressed in AML blasts, as compared to nonleukemic bone marrow cells, and insulin was able to activate PI3K/Akt and Erk in a manner comparable to IGF-I. Thus, both IGF-I and insulin may represent novel growth factors playing a crucial role in AML cell proliferation in vivo.
The IGF-IR kinase inhibitor NVP-AEW541 was able to reduce growth of AML blasts and cell lines, although differences in sensitivities were observed. In the case of some AML cell lines, high levels of expression of the IR were found in cells with reduced sensitivities to NVP-AEW541, which is in agreement with the observation that the inhibitor also blocks the protein tyrosine kinase activity of the IR at higher concentrations than the IGF-IR. 30 In support of this notion, both IGF-IR and IR neutralizing antibodies partially reduced the growth of AML cell lines. However, additional molecular mechanisms may render some AML cell lines or primary blasts resistant to IGF-IR inhibitors. Indeed, autocrine stem cell factor/c-Kit signaling was shown to reduce the sensitivity of human small cell lung cancer cells to the related IGF-IR kinase inhibitor NVP-ADW742. 43 Moreover, enhanced activation of Akt was also recently shown to protect human neuroblastoma cells from the effects of NVP-AEW541. 33 Finally, it was shown that, in hematopoietic cells transfected with the IGF-IR, pharmacological inhibitors of PI3K/ Akt/mTOR and the Raf/MEK/Erk pathways enhanced the effects of IGF-IR neutralizing antibodies. 44 Thus, a variety of mechanisms could explain the differences in sensitivities to NVP-AEW541 observed in AML blasts and cell lines. The ability of NVP-AEW541 to suppress the growth of AML cells was in part the result of induction of apoptosis, suggesting that the IGF-IR plays a role in survival of AML cells. The IGF-IR kinase inhibitor also sensitized AML cells to the chemotherapeutic agent etoposide, an observation that was previously made in other cancer cell lines. 45 Thus, IGF-IR signaling also plays a role in the resistance of AML cells to chemotherapeutic agents. Nonleukemic bone marrow cells, normal CD34
þ hematopoietic progenitors and immortalized B lymphocytes were resistant to pharmacological IGF-IR inhibitors and neutralizing antibodies, indicating that targeting IGF-IR signaling may result in selective killing of AML cells, as compared to normal leukocytes in vivo.
PI3K signaling was demonstrated to contribute to AML cell growth and survival, 46 and recent reports showed that the class I A PI3K isoform p110d plays a major role in AML cell proliferation. 47, 48 By using RNAi, we show for the first time that in addition to p110d, the PI3K isoform p110b also plays a role in AML cell growth and survival. These observations were supported by the broad expression of these two isoforms in AML blasts and cell lines. Indeed, this is the first study showing that p110b is overexpressed in most AML cases. The overexpression of p110d in AML blasts and cell lines investigated here is consistent with previous studies. 47, 48 In contrast, only low levels of p110a mRNA and protein could be found in the subset of patient samples and AML cell lines analyzed in this study. These differences could be caused by the heterogeneity and relatively small size of the samples analyzed in each study. Interestingly, RNAi or pharmacological inhibitors targeting p110b and p110d reduced Akt activation by IGF-I or insulin, implying that both PI3K isoforms can couple to the activated IGF-IR or IR in AML cells. Recent reports have demonstrated a selective role for p110a in transducing signals from the IR that control glucose homeostasis in insulin-sensitive tissues. 49, 50 However, previous reports have also documented a role for p110b in transducing signals from the IR controlling cytoskeletal rearrangements. 51 The most likely explanation for these apparent discrepancies are differences in PI3K isoform expression between the tissues/cell systems studied, since expression of p110a was detected only weakly in a subset of the AML cell lines and blasts studied here, and insulin-sensitive tissues may not express p110d. Reports concerning the expression of the PI3K antagonist PTEN in AML blasts are controversial. While variable or nondetectable PTEN expression levels have been reported in individual AML cases, 27 a subsequent study found PTEN expression in all AML cases investigated. 28 The latter findings are in line with the results obtained in the present study.
Together our data document a novel role for autocrine IGF-I/ IGF-IR signaling in the biology of human AML, which may provide novel therapeutic targets to inhibit the proliferation of leukemic cells.
